RxDoctor Payments Data

Raizel Cheng, PA

Medical · York, PANPI 1720757230

Payments from drug & device makers

$3,317in general payments, 2019–2025

Across 132 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Sumitomo Pharma America, Inc.$612
  • Johnson & Johnson$471
  • Astellas Pharma US Inc$352
  • Medtronic$184
  • Endo USA, Inc.$183
  • plus $394 from 7 others

What the payments were for

  • Travel & lodging$71321%
  • Food & beverage$2,25268%
  • Education$35311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,317 in reported general payments places this provider in the 85th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$29,782
Medicare patients
219
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron115$96,057
GemtesaVibegron64$34,661
Tamsulosin Hcl477$6,787
Mirabegron ErMirabegron16$5,543
Trospium Chloride ErTrospium Chloride25$4,359
Trospium Chloride64$3,774
Silodosin21$1,385
Finasteride102$1,091
Estradiol13$959
Alfuzosin Hcl ErAlfuzosin Hcl53$928
Solifenacin Succinate18$695
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst44$684
Testosterone Cypionate19$677
NitrofurantoinNitrofurantoin Macrocrystal11$466
Cephalexin71$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$352$96,057115 claims
Sumitomo Pharma America, Inc.Gemtesa$612$34,66164 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,594 medical providers in Pennsylvania.

Other medical in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →